Skip to main content

Bristol-Myers Value Stock - Dividend - Research Selection

Bristol-Myers

ISIN: US1101221083, WKN: 850501

Market price date: 03.04.2020
Market price: 55,53 USD




Bristol-Myers Fundamental data and company key figures of the share

Annual reports in USD
Key figures 26-02-2020
Cash flow
Net operating cash flow 8.067.000.000
Capital Expenditures -836.000.000
Free cash flow 7.231.000.064
Balance sheet
Total Equity 51.598.000.000
Liabilities & Shareholders equity 129.944.000.000
Income statement
Net income 3.439.000.000
Eps (diluted) 2,010
Diluted shares outstanding 1.710.950.000
Net sales/revenue 26.145.000.000

Fundamental ratios calculated on: 03-04-2020

Ratios
Key figures 03-04-2020
Cash flow
P/C 11,78
   
P/FC 13,14
Balance sheet
ROI2,65
ROE39,71
Income statement
P/E27,63
Div. Yield0,00%
P/B1,84
P/S3,63


Do you want to do make a detailed fundamental analysis of this stock?

Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolBMY
Market Capitalization94.461.550.592,00 USD
CountryUnited States
IndicesS&P 500
SectorsPharma
Raw Data SourceUS GAAP in Millionen USD
Stock Split2001-08-07,1000000.0000/951777.0000; 1999-03-01,2.0000/1.0000; 1997-03-03,2.0000/1.0000; 1987-06-10,2.0000/1.0000; 1983-05-27,2.0000/1.0000; 1977-05-31,2.0000/1.0000
Internetwww.bms.com


Description of the company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company\'s products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a strategic collaboration agreement with Nektar Therapeutics, Illumina, Inc., and Janssen Pharmaceuticals, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.bms.com